Rocket Lab USA (Nasdaq: RKLB) extended one of the more remarkable two-day runs in the commercial space sector on Monday, adding another 14% gain on top of Friday’s 30% surge following a blowout first quarter earnings report. The back-to-back move pushed shares to a new all-time high and left the stock up 70% on the year — a return that reflects both the strength of the company’s underlying business and a wave of investor enthusiasm for the commercial space sector being driven by the looming SpaceX IPO.
The earnings report that ignited Friday’s move was genuinely strong across every metric that matters for a company at Rocket Lab’s stage. First quarter revenue came in at $200.3 million, a 63.5% year-over-year increase, on a loss per share of $0.07 — a penny better than analyst expectations. Second quarter guidance was set at $232.5 million at the midpoint, approximately 12% above what the Street had modeled. For a company still burning cash as it scales toward profitability, the combination of accelerating revenue growth and a beat-and-raise quarter is exactly what investors needed to see.
The backlog figures are where the story gets particularly compelling. Total backlog reached $2.2 billion — up 20% in a single quarter and up 108% year-over-year. CEO Peter Beck disclosed that Rocket Lab booked 31 Electron and HASTE rocket missions during Q1, the most ever signed in a single quarter, bringing total launches in backlog across those programs to more than 70. The company also signed five new dedicated launches for Neutron, its larger next-generation rocket currently in development. A backlog growing at three-digit rates year-over-year is not a company running out of demand — it is a company struggling to build supply fast enough to meet it.
The business wins extend well beyond launch contracts. Rocket Lab was selected alongside defense contractor RTX to support the Department of Defense’s Space Based Interceptor program — providing both launch and satellite technology as part of President Trump’s Golden Dome missile defense initiative. That contract positions Rocket Lab squarely in the defense-space convergence that has been one of the most significant and durable spending tailwinds in the sector. The company also announced plans to acquire Motiv Space Systems, a robotics firm whose technology has been deployed on NASA Mars rover missions — a move that adds in-space robotics capabilities to Rocket Lab’s already expanding portfolio.
All of this is unfolding against a backdrop of accelerating investor interest in the commercial space sector broadly, catalyzed by the anticipated SpaceX IPO — expected as early as June 2026. SpaceX is not yet publicly traded, which means Rocket Lab has functioned as the go-to pure-play proxy for investors who want direct exposure to the commercial launch market. As SpaceX’s IPO timeline comes into focus, capital has been flooding into RKLB and adjacent names in anticipation.
The key question from here is whether the fundamentals can keep pace with the valuation expansion. At 70% year-to-date with all-time highs on the board, Rocket Lab is no longer a deeply discounted bet on an unproven business. It is a high-momentum, high-expectation growth story that will need continued execution — on Neutron development, defense contract delivery, and the Motiv integration — to justify where the market has taken it.
For small and microcap investors who have been in RKLB since its earlier, less recognized days: this is what the patient capital trade looks like when it works.
